

**An investigation of the mechanisms of
piperazine resistance in
Plasmodium falciparum malaria**



Megan Rose Ansbro
King's College
University of Cambridge

This dissertation is submitted for the degree of
Doctor of Philosophy

September 2019

Declaration

I hereby declare that this dissertation is the result of my own work and includes nothing which is the outcome of work done in collaboration except as specified in the text. It is not substantially the same as any work that I have submitted, or, is being concurrently submitted for a degree or diploma or other qualification at the University of Cambridge or any other University or similar institution. I further state that no substantial part of my dissertation has already been submitted, or, is being concurrently submitted for any such degree, diploma or other qualification at the University of Cambridge or any other University or similar institution. This dissertation does not exceed the prescribed 60,000 word limit for the Biology Degree Committee.

Abstract

An investigation of the mechanisms of piperazine resistance in *Plasmodium falciparum* malaria

Megan Rose Ansbro

Antimalarial drug resistance is an unrelenting obstacle to malaria control programs. In Southeast Asia (SEA), parasites have developed some degree of resistance to nearly every malaria drug currently available, with the most recent emergence to artemisinin combination therapies (ACTs). ACTs are the recommended front-line treatments for *Plasmodium falciparum* malaria worldwide and decreased susceptibility of parasites to both artemisinin and one of the widely used partner drugs, piperazine, have been reported in multiple locations in SEA. It is therefore necessary to have reliable methods for detecting and evaluating resistant phenotypes. The purpose of this study was to combine clinical data from Cambodia with findings from genomic studies to evaluate putative markers of piperazine resistance. The study first developed high-throughput assays to reliably detect one of these markers, a copy number variation (CNV) in the *plasmepsin 2* and *plasmepsin 3* (*PM2-PM3*) genes, in parasites likely to be PPQ-resistant. In addition to assay development, this study used gene overexpression techniques and CRISPR-Cas9 gene editing to examine the functional role of molecular markers of piperazine resistance, including the *PM2-3* CNV, and two gene candidates with nonsynonymous single nucleotide polymorphisms (SNPs): a putative exonuclease protein (*exo-E415G*) and a putative mitochondrial carrier protein (*mcp-N252D*). This research fills a knowledge gap in the lack of functional data for molecular markers of piperazine resistance by examining the phenotypic relevance of the genotypes observed in contemporary isolates. To complement these functional studies, this doctoral work has also used a *P. falciparum* hypermutator parasite line to select for a piperazine-resistant phenotype *in vitro*. Whole genome sequencing analysis (WGS) of the piperazine-resistant lines obtained through these experiments has identified nonsynonymous SNPs in gene candidates that have been reported to play a role in antimalarial drug resistance, including SNPs in the chloroquine resistance transporter gene (*pfert*) and the multidrug resistant protein 1 (*pfmdr1*) transporter. SNPs in *pfert* have been reported to confer piperazine resistance in the field and *in vitro* and our recent drug-pressure experiments provide additional evidence to support these findings. The WGS analysis also discovered novel SNPs in gene candidates not previously reported to modulate the piperazine-resistant phenotype that will require further evaluation. Such work has enabled the possibility of examining whether genetic changes observed in patient isolates can also be investigated and observed *in vitro*. By combining functional molecular approaches with genomic analyses, this study provides new insights into the mechanisms of piperazine resistance.

To my parents, grandparents, & Uncle Gene

Acknowledgements

I have been lucky enough to have support that spans three continents while performing my thesis work. In all the writing I have done these past couple of months (or years), this section has been the hardest to write because it feels like words cannot say “thank you” enough. Nevertheless, I will try.

To Marcus and Tom, the incredible mentors who did not have to be. Thank you for taking me on and for your mentorship and support. I have learned so much while in your labs and I will be forever grateful for the time I’ve been able to learn from you.

To Jeff Thompson and Stu Yuspa, two of my first advisors. Thank you for showing me what’s possible in the world of research and for always believing in me.

Chanaki, friend, colleague, and mentor in all things life. Thank you for showing me how to be an exemplary scientist and person.

Sophie, Brandy, Krittikorn, Manuela, and Alex: you are such inspiring scientists and people. I have learned so much from you all. Thank you for your guidance in lab and for your unending support.

To all of my lab mates in LMVR at the NIH (especially Erin, Kim, and Kristin) and on Teams 226 and 115 at Sanger, thank you for the comradery and for making cell culture enjoyable. Also, a special thank you to Liam Prestwood for ensuring all experiments can run smoothly and safely.

Thank you to all of the staff and patients in Cambodia from the field sites where this study has obtained clinical samples.

To the Gates Cambridge Scholarship, thank you for funding part of my time in Cambridge and also introducing me to an amazing community of fellow scholars and friends.

Many thanks to the amazing administrative support from the teams at LMVR and Sanger, notably Sam Moretz and Wendy Hamm, whose attention to detail is unmatched. To the NIH OxCam and Wellcome Sanger Institute graduate offices, especially Katie Soucy, Katie Stagliano, Annabel Smith, and Christina Hedberg-Delouka. Thank you also to the PaM administrative support team, especially Dee Toombs.

My friends from all over the world, notably Ash, Ingvild, Jess, Kenz, Matt, and Sandi. Thank you for always being there for me and for your optimism through it all!

My brother, Ryan, for his unwavering support, positive attitude, and sense of humor that has, and always will, remind me what is important in life.

To my husband, Levi. You have been with me every step of the way on this PhD journey. Two countries, four apartments, two cats, the highs and the lows—which have been intense on both ends. Through it all, you’ve never faltered and always believed in me and what I’m capable of. You have been a part of every word of this thesis (more literally than you may have liked). Thank you for being my partner in life. On to the next chapter!

Lastly, but certainly not least, thank you to my parents, grandparents, and Uncle Gene, for whom this thesis is dedicated. I wish my grandparents and uncle could be here to see this day, a day they helped make possible long before I even knew how big I could dream. To my mom and dad, you have given me the world. Thank you for everything.

Table of Contents

Declaration	<i>i</i>
Abstract	<i>ii</i>
Acknowledgements	<i>iv</i>
List of Figures	<i>viii</i>
List of Tables	<i>x</i>
Abbreviations	<i>xi</i>
Preface	<i>xiii</i>
Chapter 1: Introduction	<i>1</i>
1.1 Malaria: history, epidemiology, and biology	<i>1</i>
1.1.1 History of malaria	<i>1</i>
1.1.2 Malaria today: global burden and epidemiology.....	<i>3</i>
1.1.3 <i>P. falciparum</i> life cycle	<i>7</i>
1.1.4 Pathogenesis of <i>P. falciparum</i> malaria: asymptomatic, uncomplicated, severe disease	<i>10</i>
1.1.4.1 Uncomplicated <i>P. falciparum</i> malaria	<i>11</i>
1.1.4.2 Severe <i>P. falciparum</i> malaria	<i>13</i>
1.2 Antimalarial chemotherapy	<i>14</i>
1.2.1. Brief history of widely used antimalarial drugs: from monotherapies to combination therapies	<i>14</i>
1.2.1.1 Quinine.....	<i>14</i>
1.2.1.2 Chloroquine.....	<i>16</i>
1.2.1.3 Antifolates: sulfadoxine/pyrimethamine (SP), proguanil	<i>17</i>
1.2.1.4 Artemisinin.....	<i>18</i>
1.2.2.1 Combination therapies in malaria: ACTs.....	<i>19</i>
1.2.2.2 ACTs: dihydroartemisinin-piperaquine.....	<i>21</i>
1.3 Drug-resistance in <i>P. falciparum</i>	<i>23</i>
1.3.1 ACT failures: emergence of artemisinin and partner drug resistance in Cambodia	<i>23</i>
1.3.2 Assessing drug-resistance in <i>P. falciparum</i>	<i>24</i>
1.3.3 The genetic basis of resistance.....	<i>25</i>
1.3.4 The parasite digestive vacuole and antimalarial drugs	<i>26</i>
1.4 Genetic background and mechanisms of resistance in SEA	<i>28</i>
1.4.1 Chloroquine	<i>28</i>
1.4.2 Mefloquine: monotherapy and ACT.....	<i>29</i>
1.4.3 DHA-PPQ: piperaquine resistance in concert with decreased artemisinin susceptibility	<i>30</i>
1.4.4 Piperaquine resistance	<i>31</i>
1.5 Specific aims	<i>34</i>
Chapter 2: General Methodology	<i>35</i>
2.1 Cultivation of <i>Plasmodium falciparum</i>	<i>35</i>
2.1.1 <i>In vitro</i> culture maintenance	<i>35</i>
2.1.2 Determination of parasite culture hematocrit and parasitemia.....	<i>35</i>
2.1.3 Thawing and cryopreservation of parasites.....	<i>37</i>
2.1.4 Synchronization of parasites: sorbitol and Percoll gradients.....	<i>37</i>
2.1.5 Sorbitol synchronization.....	<i>38</i>
2.1.6 Percoll gradients for parasite synchronization	<i>38</i>
2.2 Parasite lines	<i>40</i>
2.2.1 Cambodian field isolates	<i>40</i>
2.2.2 Long-term laboratory-adapted parasite lines.....	<i>42</i>
2.3 Transfection of <i>P. falciparum</i> field isolates and laboratory lines	<i>43</i>
2.3.1 Transfection of <i>P. falciparum</i> using DNA-loaded red blood cells.....	<i>43</i>
2.3.2 Transfection of ring stage <i>P. falciparum</i>	<i>44</i>

2.4 Parasite cloning by limiting dilution	45
2.5 Saponin lysis and genomic DNA extraction from cultivated parasites	45
2.6 <i>In vitro</i> parasite survival assays.....	46
2.6.1 Antimalarial drug preparation.....	46
2.6.2 Drug sensitivity assays	46
2.6.3 Piperaquine survival assays (PSAs)	47
2.7 Quantification of viable parasites using flow cytometry	48
2.8 Molecular cloning techniques.....	50
2.8.1 Transformation of competent bacteria cells.....	50
2.8.2 Plasmid preparation: mini, midi, and maxi preparations	51
2.8.3 Polymerase chain reaction (PCR) protocols	51
2.8.4 DNA sequencing.....	51
<i>Chapter 3: Detection, surveillance, and evaluation of molecular markers of piperaquine resistance: plasmepsin 2-3 copy number assays and functional studies.....</i>	52
3.1 Declaration of work.....	52
3.1.1 Significance and purpose of study.....	52
3.1.2 Introduction.....	53
3.1.3 Objectives.....	55
3.2 Materials and methods	55
3.2.1 Parasite samples	55
3.2.2 <i>Plasmepsin 2-3</i> duplication breakpoint PCR assay	56
3.2.3 SYBR green validation of <i>plasmepsin 2-3</i> copy number using quantitative PCR.....	57
3.2.4 Overexpression of <i>PM2</i> and <i>PM3</i>	57
3.2.4.1 Gibson assembly of a <i>PM2</i> -only overexpression plasmid: pDC2-cam- <i>PM2</i> -2A- <i>GFP</i> -bsd-attP	58
3.2.4.2 Gibson assembly of the <i>PM2</i> -2A- <i>PM3</i> overexpression plasmid.....	59
3.2.4.3 Determination of drug selection concentration by IC ₅₀ assays	61
3.2.4.4 Use of flow cytometry to screen for pDC2-cam- <i>mRFP</i> -2A- <i>GFP</i> -bsd-attP plasmid in transfected parasites.....	62
3.3 Results.....	63
3.3.1 <i>PM2-3</i> breakpoint assay validation	63
3.3.2 <i>PM2-3</i> breakpoint assay utility in comparison with SYBR green assay.....	65
3.3.3 Analysis of <i>PM2-3</i> copy number in isolates from patients treated with artesunate-mefloquine	66
3.3.4 Overexpression of <i>PM2</i> and <i>PM3</i> in Cambodian isolates.....	67
3.3.4.1 Overexpression of <i>PM2</i> in Cambodian field isolate, 163-KH3-005	67
3.3.4.2 Confirmation of the pDC2-cam- <i>PM2</i> -2A- <i>PM3</i> plasmid and pDC2-cam- <i>mRFP</i> -2A- <i>GFP</i> -bsd-attP plasmid in transfected parasites by flow cytometry and PCR	68
3.4 Discussion and future work.....	70
<i>Chapter 4: Examination of the role of single nucleotide polymorphisms in an exonuclease protein and mitochondrial carrier protein in piperaquine resistance.....</i>	75
4.1 Declaration of work.....	75
4.1.1 Significance and purpose of study.....	75
4.1.2 Introduction.....	76
4.1.3 Objectives.....	81
4.2 Materials and methods	81
4.2.1 CRISPR-Cas9 mediated genome editing: two-plasmid system.....	81
4.2.1.1 Exonuclease <i>exo-415</i> SNP editing plasmids	81
4.2.1.2 Two-plasmid system: cloning of the gRNA and donor plasmids.....	82
4.2.2 CRISPR-Cas9 mediated genome editing: single plasmid system.....	83
4.2.3 Transfection of CRISPR-Cas9 <i>exo-415</i> and <i>mcp-252</i> plasmids.....	84
4.2.4 Screening for integration of the <i>exo</i> - and <i>mcp</i> -SNPs in transfected parasites	85

4.2.4 Drug sensitivity assays	86
4.3 Results.....	86
4.3.1 CRISPR-Cas9 editing of the exonuclease-415 SNPs: low transfection efficiency in field isolates... 86	86
4.3.2 CRISPR-Cas9 editing of the mitochondrial carrier protein-252 SNPs: low transfection efficiency in field isolates and successful editing in Dd2 parasites	88
4.3.3 Drug susceptibility profiles of the edited exonuclease and mitochondrial carrier protein SNPs in Dd2-edited parasite lines.....	91
4.3.3.1 The exo-E415G SNP does not alter parasite susceptibility to common antimalarial drugs.....	91
4.3.3.2 The mcp-N252D SNP does not alter parasite susceptibility to common antimalarial drugs	92
4.3.3.3 The exo-E415G and mcp-N252D SNPs do not alter parasite survival in piperazine survival assays	92
4.4 Discussion and future work.....	95
<i>Chapter 5: Discovery of molecular markers of piperazine resistance by in vitro drug-pressure of a hypermutator Plasmodium falciparum line.....</i>	100
5.1 Declaration of work.....	100
5.1.1 Significance and purpose of study.....	100
5.1.3 Objectives.....	105
5.2 Materials and methods	105
5.2.1 Hypermutator parasites: <i>P. falciparum</i> Dd2-polymerase δ mutants.....	105
5.2.2 Experimental design for selection of piperazine resistant Dd2-hypermutator parasites: IC ₅₀ assays and selection procedures	106
5.2.3 Preparation of PPQ-pressured parasites for whole genome sequencing analysis: cloning and genomic DNA extraction	107
5.2.4 Whole genome sequencing analysis.....	107
5.3 Results.....	108
5.3.1 Selection of piperazine-resistant Dd2-hypermutator parasites.....	108
5.3.2 Phenotypic characterization of the piperazine-pressured Dd2-polymerase δ mutant parasites	110
5.3.2.1 IC ₅₀ survival assays of piperazine-pressured Dd2-polymerase δ mutant parasites	110
5.3.2.2 Morphological differences between the PPQ-pressured parasites and the parental hypermutator line	111
5.3.3 Whole genome sequencing analysis and genetic characterization of the PPQ-pressured Dd2-hypermutator parasites.....	112
5.4 Discussion and future work.....	113
<i>Chapter 6: What's next on the resistance front? Conclusions, reflections, and future work</i>	118
<i>References.....</i>	124

List of Figures

Figure 1. 1. The global distribution of malaria in the 20th century.....	5
Figure 1. 2. The global incidence of <i>P. falciparum</i> and <i>P. vivax</i> malaria in 2017.....	5
Figure 1. 3. The life cycle of <i>P. falciparum</i>	8
Figure 1. 4. The asexual and sexual intraerythrocytic life cycles of <i>P. falciparum</i> . A.) The 48-hour life cycle of <i>P. falciparum</i>	9
Figure 1. 5. Microscopy-based malaria diagnosis is the gold standard in all malaria endemic countries...13	
Figure 1. 6. Structural similarities of antimalarial drugs.....	21
Figure 1. 7. Antimalarial drugs depicted with their proposed mechanism of action in the erythrocytic (asexual) blood stage of <i>P. falciparum</i>	22
Figure 1. 8. Timeline of antimalarial drug use for the treatment of <i>P. falciparum</i> malaria in Cambodia... ..	24
Figure 1. 9. Transmission electron microscopy of <i>P. falciparum</i> infected erythrocytes.....	33
Figure 2. 1. Schematic of Percoll gradients.....	40
Figure 2. 2. Map of Cambodia highlighting the three provinces where samples were collected during clinical trials.....	42
Figure 2. 3. Schematic for IC ₅₀ drug assay 96-well plate layout.....	47
Figure 2. 4. PSA 48-well plate setup.....	48
Figure 2. 5. Flow cytometry quantification of parasitemia using SYBR Green I and MitoTracker Deep Red.....	50
Figure 3. 1. Whole genome sequencing data displaying average coverage on chromosome 14 for isolate 163-KH1-004 (PH1345_C) as viewed using the LookSeq browser.....	56
Figure 3. 2. Plasmid design and assembly for overexpression of <i>plasmepsin 2</i> (<i>PM2</i>).....	59
Figure 3. 3. Plasmid design and assembly for overexpression of <i>PM2</i> and <i>PM3</i>	61
Figure 3. 4. Dose-response curve for field isolate 163-KH3-005 after 72-hour exposure to blasticidin (BSD).....	62
Figure 3. 5. Schematic of <i>plasmepsin 2-3</i> gene duplication.....	64
Figure 3. 6. Comparison of the breakpoint PCR and qPCR assays for measuring <i>PM2-3</i> copy numbers.. ..	66
Figure 3. 7. Proportion of samples with >1 copy or 1 copy of <i>PM2-3</i> as determined by breakpoint PCR analysis in 3 Cambodian provinces from 2014-2015.....	67
Figure 3. 8. Transgenic piperazine-sensitive parasites (005) carrying the <i>PM2</i> overexpression plasmid showed no shift in PPQ IC ₅₀ values.....	68
Figure 3. 9. Flow cytometry assessment of transgenic parasites.. ..	69
Figure 3. 10. PCR confirmation of the <i>PM2-2A-PM3</i> plasmid in transfected 005 and Dd2 parasites. PCR confirmation that the pDC2- <i>cam</i> plasmid backbone was present in transfections.....	69
Figure 4. 1. Prevalence of the <i>PM2-3</i> copy number amplification and <i>exo-E415G</i> SNP in three provinces in Cambodia from 2012-2015.	79
Figure 4. 2. Two-plasmid system for CRISPR-Cas9 editing of the exonuclease SNP.....	83
Figure 4. 3. All-in-one pDC2- <i>cam</i> -coCas9-U6-hDHFR plasmid.	84
Figure 4. 4. Primers for PCR screening of transfectants for integration of the desired locus on chromosome 13.....	86
Figure 4. 5. Sequencing analysis of the <i>exo</i> -SNP field isolate transfections that recrudesced.. ..	88
Figure 4. 6. Sequencing analysis of the <i>mcp</i> -SNP field isolate transfection post-recrudescence.....	90
Figure 4. 7. Sequencing analysis of the Dd2- <i>mcp</i> -SNP transfections.....	91
Figure 4. 8. The <i>exo-E415G</i> SNP has no effect on IC ₅₀ values or susceptibility to PPQ and other commonly used antimalarial drugs.....	93
Figure 4. 9. The <i>mcp-N252D</i> SNP has no effect on IC ₅₀ values or susceptibility to PPQ and other commonly used antimalarial drugs.	94
Figure 4. 10. The Dd2 transgenic <i>exo-E415G</i> and <i>mcp-N252D</i> edited SNPs have no effect on parasite survival to PPQ in piperazine survival assays (PSAs).	95
Figure 5. 1. Alignment of the DNA polymerase δ amino acid sequence highlighting the conserved residues in the 3'→5'exonuclease domain.....	105

Figure 5. 2. Determination of PPQ concentration to use for selection of PPQ-resistant Dd2-polymerase δ mutant parasites	107
Figure 5. 3. Initial attempt (experiment 1) for selection of piperazine (PPQ)-resistant Dd2-hypermulator parasite lines	108
Figure 5. 4. Second attempt (experiment 2) for selection of piperazine (PPQ)-resistant Dd2-hypermulator parasite lines.....	109
Figure 5. 5. Comparison of PPQ susceptibility between the parental Dd2-polymerase δ hypermutator parasite and the PPQ-pressured lines.....	111
Figure 5. 6. Morphological difference between the parental Dd2-polymerase δ hypermutator parasite and a PPQ-pressured line	112

List of Tables

Table 2. 1 Summary of Cambodian field isolates and laboratory strains used in this study	41
Table 3. 1 Primers for the development of <i>PM2-PM3</i> overexpression plasmids.....	60
Table 4. 1 Top GWAS candidate SNPs associated with increased piperazine IC50 values	78
Table 4. 2 gRNA sequences in the donor plasmids for the <i>exo-415</i> and <i>mcp-252</i> CRISPR-Cas9 plasmids	82
Table 4. 3 Primers used to screen for integration of SNPs.....	86
Table 4. 4 CRISPR-Cas9 transfections and outcomes of <i>exo-415</i> SNP editing experiments in Cambodian field isolates.....	87
Table 4. 5 CRISPR-Cas9 transfections and editing efficiency of the <i>mcp-252</i> SNPs in Cambodian field isolates and <i>Dd2</i>	89
Table 5. 1 Non-synonymous SNPs discovered in the PPQ-pressured <i>Dd2</i> -hypermutator lines	113

Abbreviations

ACT	Artemisinin Combination Therapy
AQ	amodiaquine
AS	artesunate
bp	base pair
BSD	blasticidin
CNV	copy number variation
CPDA	citrate-phosphate-dextrose-adenine
CQ	chloroquine
CRISPR	Clustered Regularly Interspaced Short Palindromic Repeats
DHA	dihydroartemisinin
DV	digestive vacuole
exo-E415G	exonuclease SNP, E415G
FNT	formate-nitrite transporter
gRNA	guide RNA
GWAS	genome-wide association study
Hb	hemoglobin
hDHFR	human dihydrofolate reductase
IC50	inhibitory concentration assay
iRBCs	parasite-infected red blood cells
K13	kelch13
ldh	lactate dehydrogenase
LUM	lumefantrine
mcp-N252D	mitochondrial carrier protein SNP, N252D
MQ	mefloquine
MRP2	multidrug resistance-associated protein 2
NHEJ	non-homologous end joining
PCR	polymerase chain reaction
PfCRT	chloroquine resistance transporter
PfMDR1	multidrug resistance protein 1
PM2	plasmepsin 2
PM3	plasmepsin 3
PPQ	piperaquine
PPQ-R	piperaquine-resistant
PPQ-S	piperaquine-sensitive
pRBCs	packed red blood cells
PSA	piperaquine survival assay
RBC	red blood cell
RSA	ring stage survival assay
SD	standard deviation
SEA	Southeast Asia
SNP	single nucleotide polymorphism
TACT	Triple Artemisinin Combination Therapy
TRAC	Tracking Resistance to Artemisinin Collaboration

uRBCs
WGS
WWARN

uninfected red blood cells
whole genome sequencing
Worldwide Antimalarial Research Network

Preface

How does a disease that we have known about for thousands of years—for which we have cures—still cause nearly half a million deaths each year? This question has driven the entirety of this thesis project. By focusing on one facet of the complex problem, the intricate biology of the malaria parasite, this doctoral dissertation attempts to provide insight into the role that drug resistance plays in the treatment of *Plasmodium falciparum* malaria. Though the goal of this work was never to answer the overarching question explicitly, it continues to hold the larger perspective and impact of this devastating disease at the forefront of this research.

